Viral infections in prostate carcinomas in Chilean patients

Hector Rodríguez¹, Jorge Levican², Juan P. Muñoz², Diego Carrillo², Mónica L. Acevedo², Aldo Gaggero², Oscar León², Tarik Gheit³, Omar Espinoza-Navarro⁴, Jorge Castillo⁵, Iván Gallegos⁶, Massimo Tommasino³ and Francisco Aguayo²*

Abstract

Background: A few viruses have been detected in prostate cancer, however their role in the development of this malignancy has not been determined. The aim of this study was to analyze the presence and functionality of human papillomavirus (HPV) and polyomaviruses (BKPyV and JCPyV) in prostate carcinomas in Chilean patients.

Methods: Sixty-nine primary prostate carcinomas were analyzed for the presence of HPV, BKPyV and JCPyV using standard polymerase chain reaction protocols. In addition, when samples were positive for HPyV, large T antigen (TAg) transcripts were analyzed using reverse transcriptase PCR.

Results: HPV and JCPyV were not detected in any specimens (0/69, 0%); whereas, BKPyV was detected in 6/69 PCAs (8.7%). We did not find a statistically significant association between the presence of BKPyV and age (p = 0.198) or Gleason score (p = 0.268). In addition, 2/6 (33%) BKPyV positive specimens showed detectable levels of TAg transcripts.

Conclusions: There was no association between HPV or JCPyV presence and prostate cancer development. The presence of BKPyV in a small subset of prostate carcinomas in Chilean patients could indicate that this virus plays a potential role in prostate cancer development and requires further investigation.

Keywords: Prostate, Cancer, Virus

Introduction

Prostate cancer (PCa) is the second most common cancer worldwide [1], and is particularly common in industrialized countries. In Chile, the incidence rate of PCa is 27.9/100,000 inhabitants and its mortality rate is 15.6/100,000 inhabitants [1]. Human papillomavirus (HPV) and polyomaviruses (HPyV) are small non-enveloped DNA viruses that have been detected at variable frequencies in PCAs worldwide. However, the etiological role of these viruses has only been established in specific tumors. For example, high-risk HPVs are the causal agent of cervical, anogenital and a subset of oropharyngeal carcinomas [2]. In addition, there is convincing evidence that Merkel cell polyomavirus (MCPyV) is the etiological agent of Merkel cell carcinomas [3]. Although the DNA of both HPV and HPyV has been detected in PCAs, there is high variability in the detection rates between different studies. Nevertheless, the mere detection of viral DNA fragments in clinical specimens is not sufficient to indicate causality. Previous reports have described the presence of HPV in biopsies of PCa and prostatic benign hyperplasia [4–8]. However, a recent meta-analysis concluded that high-risk HPV-16 and −18 did not contribute to increased PCa risk [9]. The reported frequencies of HPyVs, and in particular BKPyV, in PCa have been inconsistent [10–13]; while other studies have proposed that BKPyV is not involved in PCa [14, 15]. JCPyV is the etiologic agent of progressive multifocal leukoencephalopathy (PML), a neurodegenerative disease [16]. It has been suggested that the presence of JCPyV correlates with various types of human neoplasm, including colorectal, gastric, prostatic, oesophageal, brain and bronchial carcinomas and B cell lymphomas [17]. However, an oncogenic role for this
virus has not been definitively established. Taken together, the definitive role of viral infections, such as HPV, BKPyV and JCPyV, in prostate carcinogenesis has not been established. Thus the aim of this study was to determine the presence of HPV, BKPyV and JCPyV in PCas in patients at two public hospitals in Santiago, Chile, and to analyze the expression levels of viral onco-
genomes in virus-positive PCas samples.

Materials and methods

Clinical samples

For this retrospective study, formalin-fixed and paraffin-embedded specimens from PCas confirmed by histo-

diagnostic analysis were used. Samples were collected at San Borja Arriarán Hospital (thirty one samples from 2004 to 2012) and at José Joaquin Aguirre Hospital (thirty eight samples, from 2005 to 2009) in Santiago, Chile. The participants did not provide their written or verbal informed consent to participate in this study. Under Chilean law, informed consent is not necessary if the analysis does not pertain to the human genome. Only viral DNA sequences were analyzed in this study, which was approved by the Ethics Committee of the José Joaquin Aguirre Hospital, Faculty of Medicine, Universidad de Chile.

DNA extraction and detection of viral infections

Paraffin tissue sections were incubated with digestion buffer (10 mM Tris–HCl pH 7.4, 0.5 mg/mL proteinase K and 0.4 % Tween 20) at 37 °C for 3 h. Afterwards, the samples were incubated for 10 min at 95 °C, centrifuged for 2 min at 14,000 rpm and immediately placed on ice. After centrifugation, the aqueous phase was transferred to a new tube [18].

HPV typing was performed by a type-specific multiplex genotyping (TS-MPG) assay, which combines multiplex PCR and bead-based Luminex Technology, as previously described [19–21]. This assay is able to detect DNA from 19 alpha mucosal HPV types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73 and 82). In addition, we used conventional PCR with the GP5+/6+ primers as an alternative technique for HPV detection. DNA quality was determined by PCR using the betaglobin gene fragment as a marker with the following primers: PCO3 5′-ACACAACTGTGTTCACTAGC-3′ and PCO4 5′-CAACTTCCATCAGGTGTCAAC-3′. The amplification program was as follows: denaturation at 95 °C for 5 min, 45 cycles with a cycling profile of 95 °C for 30 s, 52 °C for 30 s, 72 °C for 30 s and final extension at 72 °C for 5 min. For HPV amplification we used the following primers: GP5+ 5′-TTTGGTATTCTGTTAGATATC-3′ and GP6+ 5′-GAAAAATAAACTGTAATCATTTCC-3′. The PCR conditions were as follows: denaturation at 95 °C for 1 min, 52 °C for 2 min, 72 °C for 1.5 min and a final extension at 72 °C for 5 min. The amplification products were stained with MasterSafe (Promega), visualized under UV transillumination and photographed.

BKPyV detection was conducted using qPCR with an intercalating dye format as previously reported [22]. Briefly, a 127 bp fragment of the BKPyV genome was amplified with the following BK127-F and BK127-R primers: BK127-F: 5′-GCA GCT CCC AAA AAG CCA AA-3′ and BK127-R: 5′-CTG GGT TTA GGA AGC ATT CTA-3′. The 20 μL final volume reactions contained 1X LightCycler® FastStart DNA Master SYBR Green I (Roche Diagnostics, Indianapolis, IN, USA), 0.5 μM of each primer, 3.0 μM MgCl2 and 5 μL of DNA template. The PCR reaction was run for 40 cycles as follows: denaturation as 94 °C for 10 s, annealing at 62 °C for 10 s and extension at 72 °C for 10 s, with an initial denaturation at 95 °C for 15 min and final extension at 72 °C for 10 min. The amplification products were subjected to a melting profile and the specific product was characterized according to its Tm.

JCPyV was detected using real-time qPCR with JE3 primers and a JE3 probe set (JE3-(Mad-1)F 5′-ATGTTTGGCAGTGATGATGAAAA-3′, JE3-(Mad-1)R 5′-GAAAGGTTAAGGCTCTTCTACTTCTT-3′ and JE3-(Mad-1)Probe 5′-FAM-AGGATCCCCAACACTCTACCCCACCTAAAGAGA-BHQ1-3′) according to a previously described protocol [23, 24]. The PCR reaction contained 1X Brilliant® II QRT-PCR Master Mix (Agilent Technologies Santa Clara, CA, USA), 0.5 μM of each primer, 0.15 μM of probe and 5 μL of DNA in a total volume of 25 μL. The amplification conditions were as follows: 95 °C for 10 min, followed by 50 cycles with denaturation at 95 °C for 15 s and annealing/extension at 60 °C for 1 min. The sensitivity for JCPyV and BKPyV detections by qPCR was 40 viral copies in 20 μL of reaction mix.

Large T antigen (TAg) transcript detection

RNA purification was carried out using the High Pure RNA paraffin kit (Roche), following the manufacturers’ instructions. The RNA was suspended in 50 μL of TE (10 mM Tris–Cl, 1 mM EDTA) and stored at −80 °C until use. The RNA was incubated for 1 h at 37 °C with RQ1 DNAase and the enzyme was inactivated by incubation at 70 °C during 10 min. The cDNA preparation was made in accordance with the conditions established by the manufacturer using M-MLV reverse transcriptase (Promega). Negative controls without M-MLV were included. The reaction mixture was incubated at 37 °C for 1 h and stored at −20 °C. We used GAPDH amplification as a constitutive expression control, according to a previously reported protocol [25]. The amplification of TAg transcripts was carried out using the following
primers: BKF: 5′-AGC CAC ACC CAG TTC AAA AG-3′ and BKR: 5′-AAA CAA CAC TAG CTG CAG GG-3′. The 25-μL final volume reactions contained 1X Buffer (Promega), 0.4 μM of each primer, 1.5 μM MgCl₂ and 1 μL of cDNA template. The amplification program was as follows: initial denaturation at 95 °C for 5 min followed by 45 cycles consisting of denaturation at 94 °C for 1 min, annealing at 55 °C for 1 min and extension at 72 °C for 1 min, followed by a final extension at 72 °C for 5 min. The amplification products (98 bp) were stained with MasterSafe (Promega), visualized under UV transillumination and photographed.

Statistical analysis
Statistical analysis was performed using the Fisher’s exact test with the Stata 13.0 software. A p-value of less than 0.05 was considered statistically significant.

Results
In this study we determined the presence of HPV, BKPyV and JCPyV in PCas in Chilean patients. Sixty-nine PCa samples obtained from patients at two public hospitals in Santiago, Chile were selected. Table 1 shows the clinical-pathological characteristics of patients included in this study. The mean age was 63 ± 6 years and the mean Gleason score of the tumors was 6.98 ± 1.10, with a range of 2 to 9. Age did not differ between the two hospitals (p = 0.336). However, we found that the Gleason score was significantly different between the two hospitals; patients treated at the J. J. Aguirre Hospital had a higher Gleason score compared to patients treated at the Barros Luco Hospital (p = 0.006).

Amplification of a 110 bp fragment of b-globin gave a similar yield in all samples. Using a highly sensitive genotyping assay (TS-MPG), HPV genomes were not detected in any of the samples. In addition, the absence of HPV genomes in all samples was confirmed by an independent GP5+/6+ PCR assay [26]. In contrast, for polyomaviruses we found that 6/69 (8.7 %) samples were positive by qPCR for BKPyV. Table 2 shows BKPyV detection and its association with clinical-pathological features. No statistically significant differences were found between age (p = 0.198), Gleason score (p = 0.268) or hospital (p = 0.402) and BKPyV presence in PCa. The dissociation curves for BKPyV and melting analysis of BKPyV positive and negative cases are shown in the Fig. 1.

Finally, we determined the expression of the TAg at the RNA level in BKPyV positive cases. Table 3 shows the expression of TAg in BKPyV positive cases along with hospital, age and Gleason score.

Discussion
PCa is a biologically heterogeneous tumor affecting men that involves multiple factors in its etiology [27]. Several risk factors for PCa have been identified, such as age, familiar history, ethnicity, diet and environment [28]. In addition, molecular alterations involved in PCa development have been well characterized, and some alterations in specific pathways have been identified, such as the androgen receptor pathway, phosphatidylinositol 3-kinase (PI3K) and functional loss of the prostate tumor suppressor NKX3.1, among others [29]. In this context, the potential role of HPV or HPyVs infections in the development of this malignancy has been investigated previously. It must be mentioned that in order to establish a causal relationship between HPV or HPyVs and PCa development, some questions need to be answered. First, is it biologically possible for HPV or HPyVs to be involved in prostate cancer development? In this respect, Choo et al. were able to immortalize prostate epithelial cells with HPV-16 E6/E7 oncogenes (PI3K) and functional loss of the prostate tumor suppressor NKX3.1, among others [29]. In this context, the potential role of HPV or HPyVs infections in the development of this malignancy has been investigated previously. It must be mentioned that in order to establish a causal relationship between HPV or HPyVs and PCa development, some questions need to be answered. First, is it biologically possible for HPV or HPyVs to be involved in prostate cancer development? In this respect, Choo et al. were able to immortalize prostate epithelial cells with HPV-16 E6/E7 oncogenes (PI3K) and functional loss of the prostate tumor suppressor NKX3.1, among others [29]. In this context, the potential role of HPV or HPyVs infections in the development of this malignancy has been investigated previously. It must be mentioned that in order to establish a causal relationship between HPV or HPyVs and PCa development, some questions need to be answered. First, is it biologically possible for HPV or HPyVs to be involved in prostate cancer development? In this respect, Choo et al. were able to immortalize prostate epithelial cells with HPV-16 E6/E7 oncogenes (PI3K) and functional loss of the prostate tumor suppressor NKX3.1, among others [29]. In this context, the potential role of HPV or HPyVs infections in the development of this malignancy has been investigated previously. It must be mentioned that in order to establish a causal relationship between HPV or HPyVs and PCa development, some questions need to be answered. First, is it biologically possible for HPV or HPyVs to be involved in prostate cancer development? In this respect, Choo et al. were able to immortalize prostate epithelial cells with HPV-16 E6/E7 oncogenes (PI3K) and functional loss of the prostate tumor suppressor NKX3.1, among others [29]. In this context, the potential role of HPV or HPyVs infections in the development of this malignancy has been investigated previously. It must be mentioned that in order to establish a causal relationship between HPV or HPyVs and PCa development, some questions need to be answered. First, is it biologically possible for HPV or HPyVs to be involved in prostate cancer development? In this respect, Choo et al. were able to immortalize prostate epithelial cells with HPV-16 E6/E7 oncogenes (PI3K) and functional loss of the prostate tumor suppressor NKX3.1, among others [29]. In this context, the potential role of HPV or HPyVs infections in the development of this malignancy has been investigated previously. It must be mentioned that in order to establish a causal relationship between HPV or HPyVs and PCa development, some questions need to be answered. First, is it biologically possible for HPV or HPyVs to be involved in prostate cancer development? In this respect, Choo et al. were able to immortalize prostate epithelial cells with HPV-16 E6/E7 oncogenes (PI3K) and functional loss of the prostate tumor suppressor NKX3.1, among others [29]. In this context, the potential role of HPV or HPyVs infections in the development of this malignancy has been investigated previously. It must be mentioned that in order to establish a causal relationship between HPV or HPyVs and PCa development, some questions need to be answered. First, is it biologically possible for HPV or HPyVs to be involved in prostate cancer development? In this respect, Choo et al. were able to immortalize prostate epithelial cells with HPV-16 E6/E7 oncogenes (PI3K) and functional loss of the prostate tumor suppressor NKX3.1, among others [29]. In this context, the potential role of HPV or HPyVs infections in the development of this malignancy has been investigated previously.

Table 2 BKPyV presence in prostate cancer in relation to clinical-pathological features

| Number of subjects (%) | BKPyV (-) | BKPyV (+) | p-value |
|------------------------|-----------|-----------|---------|
| Total                  | 63 (100)  | 6 (100)   |         |
| Age                    |           |           |         |
| <65                    | 33 (52.4) | 1 (16.7)  | 0.198   |
| ≥65                    | 30 (47.6) | 5 (83.3)  |         |
| Gleason Low            | 22 (34.9) | 2 (33.3)  | 0.268   |
| Medium                 | 27 (42.9) | 1 (16.7)  |         |
| High                   | 14 (22.2) | 3 (50.0)  |         |
| Hospital               |           |           |         |
| Barros Luco            | 27 (42.9) | 4 (66.7)  | 0.402   |
| José J. Aguirre        | 36 (57.1) | 2 (33.3)  |         |

*Indicates a statistically significant difference by hospital
functional TAg is required [32]. Thus, it seems biologically possible that both viruses may be able to transform prostate cells and could potentially be involved in prostate carcinogenesis. The second question is: Is this biological relationship epidemiologically important to PCa development? This is a controversial topic for the reasons mentioned previously. In particular, the reported rate of HPV infection in PCa varies worldwide [9], and specifically it has been suggested that the male genital tract or the sperm may be a reservoir for the presence of this virus [33]. The role of HPV in PCa development has been evaluated in many studies [9]; however, findings have been inconclusive [34]. In the present study, using two different PCR-based approaches we were not able to detect HPV DNA sequences in PCa samples. Although our results suggest that HPV is probably not related to this malignancy, we cannot strictly rule out a “hit and run” mechanism, as has been previously suggested for the HPV-18 genotype [35]. JCPyV has previously been reported in benign prostate hyperplasia (BPH) and in PCa, suggesting that it is probably a bystander infection in the prostate [10]. Moreover, it was reported that JCPyV was frequently present in normal prostate specimens, suggesting that this virus replicates in the prostate epithelium [36]. In this study we were not able to detect JCPyV infection in any of the PCa specimens, suggesting that this virus is not related to the development of this disease. BKPyV was detected in 8.7% of PCa specimens, and 33% of BKPyV positive specimens expressed the TAg. It has been previously

Table 3 Large T antigen expression and clinical features for BKPyV positive prostate cancers

| Patient | Hospital | Age | Gleason | TAg |
|---------|----------|-----|---------|-----|
| 1       | BL       | 65  | 6       | -   |
| 2       | BL       | 65  | 7       | -   |
| 3       | JJA      | 67  | 8       | +   |
| 4       | JJA      | 57  | 8       | -   |
| 5       | BL       | 67  | 8       | +   |
| 6       | BL       | 68  | 6       | -   |

BL Barros-Luco Hospital, JJA José Joaquin Aguirre Hospital

Fig. 1 Dissociation curves and melting analysis of BKPyV positive and negative cases. The observed Tm was 80.8ºC.
reported that this oncoprotein is able to bind and inactivate pRb and p53 tumor suppressor proteins, frequently downregulated in cancer, and specifically in viral-induced tumors [37]. Thus our results suggest that in the 33 % of BKPyV positive cases an oncogenic role of BKPyV is plausible. However, the limitations of this study are that our methodological approach does not allow us to determine if the viral infection is present in each tumor cell, as the original specimen contains adjacent non-tumor cells. The use of microdissection or in situ methodological approaches will be necessary in future studies.

Given our findings, a third question arises: Is the presence of BKPyV in PCa clinically relevant? In this respect, it is plausible that the presence of oncogenic viruses with functional activity is related to changes in the behavior of the tumor, and consequently be related to clinical observations. It has been previously established that patients positive for high-risk HPV with oropharyngeal carcinomas have better outcomes and higher rates of survival compared to HPV negative patients [38]. However, such a relationship for viral infections in the prostate, and specifically for BKPyV, has not been established. In our study we did not find a statistically significant association between BKPyV infection and age, even though 87 % of BKPyV infections were detected in subjects over 65 years of age. This finding is compatible with the reactivation of this virus in the elderly or those under immunosuppressed conditions. In addition, 50 % of BKPyV positive patients showed a high Gleason score as compared to 22 % of BKPyV negative patients, although this difference was not statistically significant. Although this virus is acquired in early childhood, the transmission route is unknown, but is likely through oral or gastrointestinal mucosa, and disseminated into the kidneys where the virus develops a persistent infection [39, 40]. In this respect it has been suggested that rearranged noncoding control regions (NCCRs) of polyomaviruses altering the number and composition of transcription factor binding sites (TFBSs) are involved in silent persistence and reactivation [41]. In addition, it has been reported that BKPyV downregulates Toll like receptor 9 (TLR9) raising the possibility that such downregulation is involved in viral persistence [42]. In fact, it was established that 90 % of the population is serologically positive for BKPyV infection [43].

In conclusion, in this study we determined that BKPyV was present in a discrete number of prostate cancers in Chilean patients, with partial detection of TAg antigen in BKPyV positive specimens, suggesting a causal association in a subset of cases. More studies are warranted to elucidate the clinical significance of these findings.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
HR got the clinical specimens, collected and tabulated the clinical information and critical revision of the manuscript. JL carried out the PCR assays for polyomaviruses. JM carried out the PCR assays for papillomaviruses. DC carried out the PCR assays confirmation for papillomaviruses. MA participated in the data analysis, statistical support and critical revision. AG participated in technical support for polyomavirus detection, data analysis and critical revision. OL carried out a critical revision of the manuscript, data analysis and methodological support for virus detection. TG gave technical support for papillomavirus detection using PCR-Luminex. OE. Participated in collection of clinical specimens and patients information. JL. Participated in collection of clinical specimens and patients information. IG collected of clinical specimens, pathological diagnosis and support for clinical information. MT gave technical support and reagents for papillomavirus detection using PCR-Luminex. FA. Analyzed the data and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgments
This study was supported by Fondecyt Grant 1120248 to FA.

Author details
1Anatomy and Development Biology Program, Institute of Biomedical Sciences (ICBM), Faculty of Medicine, Universidad de Chile, Santiago, Chile. 2Virology Program, Institute of Biomedical Sciences (ICBM), Faculty of Medicine, Universidad de Chile, Santiago, Chile. 3Infections and Cancer Biology Group, International Agency for Research on Cancer (IARC), Lyon, France. 4Biology Department, Universidad de Tarapacá, Tarapacá, Chile. 5Pathological Anatomy Department, Barros Luco-Trudeau Hospital, Universidad de Chile, Santiago, Chile. 6Pathological Anatomy Service, Clinical Hospital, Universidad de Chile, Santiago, Chile.

Received: 2 July 2015 Accepted: 17 August 2015
Published online: 01 September 2015

References
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136(5):E359-E86.
2. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009;384(2):260-5.
3. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096-100.
4. Moyret-Lalle C, Marçais C, Jacquemier J, Moles JP, Davet A, Soret JI, et al. p53 and HPV status in benign and malignant prostate tumors. Int J Cancer. 1995;64(2):124-9.
5. Cuzick J. Human papillomavirus infection of the prostate. Cancer Surv. 1995;2391-5.
6. Leiros GS, Galliano SR, Sember ME, Kahni T, Schwarz E, Eiguchi K. Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urol. 2005;5:15.
7. Whitaker NJ, Glenn WK, Sahrudin A, Orde MM, Delprado W, Lawson JS. Human papillomavirus and Epstein Barr virus in prostate cancer: Kilocytes indicate potential oncogenic influences of human papillomavirus in prostate cancer. Prostate. 2013;73(3):236-41.
8. Martinez-Fierro ML, Leach RJ, Gomez-Guerra LS, Garza-Guajardo R, Johnson-Pais T, Beuten J, et al. Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer. 2010;10:326.
9. Lin Y, Mao Q, Zheng X, Yang K, Chen H, Zhou C, et al. Human papillomavirus 16 or 18 infection and prostate cancer risk: a meta-analysis. J Int Med Res. 2011;39(2):497-503.
10. Delbue S, Matei DV, Cafton C, Pecchenni V, Carluccio S, Villani S, et al. Evidence supporting the association of polyomavirus BK genome with prostate cancer. Med Microbiol Immunol. 2013;202(6):425-30.
11. Balis V, Sourvinos G, Soulitzi N, Giannikaki E, Sofras F, Spanidios DA. Prevalence of BK virus and human papillomavirus in human prostate cancer. Int J Biol Markers. 2007;22(4):245-51.
12. Das D, Wojno K, Imperiale MJ. BK virus as a cofactor in the etiology of prostate cancer in its early stages. J Virol. 2006;80(8):2705-14.
13. Russo G, Arzovino E, Fioriti D, Mischietti M, Bellizzi A, Giordano A, et al. p53 gene mutation rate. Gleason score, and BK virus infection in prostate adenocarcinoma: Is there a correlation? J Med Virol. 2008;80(12):2100–7.

14. Akgül B, Pfister D, Knüchel R, Heidemrich A, Wieland U, Pfister H. No evidence for a role of xenotropic murine leukemia virus-related virus and BK virus in prostate cancer of German patients. Med Microbiol Immunol. 2012;201(2):245–8.

15. Laiu SK, Lacey SF, Chen YY, Chen WG, Weiss LM. Low frequency of BK virus in prostatic adenocarcinomas. APMIS. 2007;115(9):536–9.

16. Bellizzi A, Nardis C, Arzovino E, Rodio D, Fioriti D, Mischietti M, et al. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. J Neurovirol. 2012;18(1):11–11.

17. Reiss K, Khalili K. Viruses and cancer: lessons from the human polyomavirus, JCV. Oncogene. 2003;22(42):6517–23.

18. Gheit T, Vaccarella S, Schmitt M, Pawlita M, Franceschi S, Sankaranarayanan R, et al. Prevalence of human papillomavirus types in cervical and oral cancers in central India. Vaccine. 2009;27(5):536–9.

19. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol. 2006;44(2):504–12.

20. Schmitt M, Donodog B, Waterboer T, Pawlita M, Tommasino M, Gheit T. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol. 2010;48(11):143–9.

21. Gheit T, Lanni S, Gemignani F, Snijders PJ, Vaccarella S, Franceschi S, et al. Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol. 2006;44(6):2025–31.

22. Randhawa P, Ho A, Shapiro R, Vats A, Swalsky P, Finkelstein S, et al. Correlates of quantitative measurement of BK polyomavirus (BKV) DNA with clinical course of BKV infection in renal transplant patients. J Clin Microbiol. 2004;42(5):1176–80.

23. Albinana-Gimenez N, Miagostovich MP, Calgua B, Huguet JM, Matia L, Peña N, Carrillo D, Muñoz JP, Chnaiderman J, Urzúa U, León O, et al. Human polyomavirus infection and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol. 2006;44(6):2025–31.

24. Pal A, Sirota L, Maudru T, Peden K, Lewis AM. Real-time, quantitative PCR assays for the detection of virus-specific DNA in samples with mixed populations of polyomaviruses. J Virol Methods. 2006;135(1):32–42.

25. Peña N, Carrillo D, Muñoz JP, Chnaiderman J, Urzúa U, León O, et al. Tobacco smoke activates human papillomavirus 16 p97 promoter and cooperates with high-risk E6/E7 for oxidative DNA damage in lung cells. PLoS One. 2015;10(4):e0123029.

26. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. HIV and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol. 2006;44(6):2025–31.

27. Albinana-Gimenez N, Miagostovich MP, Calgua B, Huguet JM, Matia L, Girones R. Analysis of adenoviruses and polyomaviruses quantified by qPCR as indicators of water quality in source and drinking-water treatment plants. Water Res. 2009;43(7):2011–9.

28. Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol. 2009;6(2):87–95.

29. Shaposhnikova E, Beer TM, Evans CP. Molecular pathways and targets in cancer. J Med Virol. 2010;82(10):1636–45.

30. Choo CK, Ling MT, Chan KW, Tsao SW, Zheng Z, Zhang D, et al. Risk factors for prostate cancer: no conclusive evidence for a link. A systematic review. Urol Oncol. 2012;31(7):951–65.

31. Iwatake T, Hayashi Y, Yokoyama M, Hara K, Matsu N, Sugimori H. ‘Hit and run’ oncogenesis by human papillomavirus type 18 DNA. Acta Obstet Gynecol Scand. 1992;71(3):219–23.

32. Zambrano A, Kalantari M, Simoneau A, Jensen JL, Villarreal LP. Detection of human polyomaviruses and papillomviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. Prostate. 2002;53(4):263–76.

33. Harris KE, Chang E, Christensen JB, Imperiale MJ. BK virus as a potential co-factor in human cancer. Dev Biol Stand. 1998;94:181–91.

34. Lowy DR, Munger K. Prognostic implications of HPV in oropharyngeal cancer. N Engl J Med. 2010;363(1):82–4.

35. Boffill-Mas S, Formiga-Cruz M, Clemente-Casares P, Calafell F, Girones R. Potential transmission of human papillomaviruses through the gastrointestinal tract after exposure to virions or viral DNA. J Virol. 2001;75(21):10290–9.

36. Babel N, Volk HD, Reinke P. BK polyomavirus infection and nephropathy: the virus-immune system interplay. Nat Rev Nephrol. 2011;7(7):399–406.

37. Bethge T, Hachemi HA, Manzetti J, Gose G, Schaffner W, Hirsch HH. Sp1 sites in the noncoding control region of BK polyomavirus are key regulators of bidirectional viral early and late gene expression. J Virol. 2015;89(6):3396–411.

38. Shahzad N, Shuda M, Gheit T, Kwan HJ, Cornel C, Saidj D, et al. The T antigen locus of Merkel cell polyomavirus downregulates human Toll-like receptor 9 expression. J Virol. 2013;87(23):13009–19.

39. Knowles WA. Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol. 2006(577):19–45.